These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8251903)

  • 1. Disease progression in a murine model of bcr/abl leukemogenesis.
    van Etten RA
    Leuk Lymphoma; 1993; 11 Suppl 1():239-42. PubMed ID: 8251903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blast crisis in a murine model of chronic myelogenous leukemia.
    Daley GQ; Van Etten RA; Baltimore D
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11335-8. PubMed ID: 1763047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
    Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
    Warmuth M; Danhauser-Riedl S; Hallek M
    Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
    Gishizky ML; Johnson-White J; Witte ON
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3755-9. PubMed ID: 8475126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
    Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
    Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
    Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
    Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
    Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
    Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myelogenous leukemia: mechanisms underlying disease progression.
    Shet AS; Jahagirdar BN; Verfaillie CM
    Leukemia; 2002 Aug; 16(8):1402-11. PubMed ID: 12145676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
    Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
    Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models of BCR/ABL-induced leukemias.
    Daley GQ
    Leuk Lymphoma; 1993; 11 Suppl 1():57-60. PubMed ID: 8251918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.